<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4134"><DrugName>pirsidomine</DrugName><DrugNamesKey><Name id="42756304">pirsidomine</Name></DrugNamesKey><DrugSynonyms><Name><Value>CAS-936</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>pirsidomine</Value><Types><Type>INN</Type></Types></Name><Name><Value>C87-3754</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>132722-74-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25224">Hoechst Marion Roussel Inc</CompanyOriginator><CompaniesSecondary><Company id="25224">Hoechst Marion Roussel Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4134" type="Drug"><TargetEntity id="177879" type="siDrug">Pirsidomine</TargetEntity></SourceEntity><SourceEntity id="25224" type="Company"><TargetEntity id="4295910625" type="organizationId">Aventis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="23" type="ciIndication"><TargetEntity id="I20" type="ICD10"></TargetEntity><TargetEntity id="10002383" type="MEDDRA"></TargetEntity><TargetEntity id="D000787" type="MeSH"></TargetEntity><TargetEntity id="-1965112918" type="omicsDisease"></TargetEntity><TargetEntity id="223" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="492" type="Action"><TargetEntity id="5055" type="Mechanism">Soluble Guanylate Cyclase (sGC) Activators</TargetEntity><TargetEntity id="528" type="Mechanism">Guanylate Cyclase Activators</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="178">Hypertension</Indication><Indication id="23">Angina</Indication></IndicationsSecondary><ActionsPrimary><Action id="492">Guanylate cyclase stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action><Action id="277">NO receptor agonist</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T09:33:28.000Z</LastModificationDate><ChangeDateLast>2002-03-21T15:16:10.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Hoechst Marion Roussel has discontinued the development of &lt;ulink linkID="4134" linkType="Drug"&gt;pirsidomine&lt;/ulink&gt;, a nitric oxide (NO) donor vasodilator for the potential treatment of angina and hypertension. The compound was being developed as a follow up to molsidomine in iv (CAS-754) and oral (CAS-936) formulations, and had reached phase II clinical trials in the US, Europe and Japan. &lt;ulink linkID="4134" linkType="Drug"&gt;Pirsidomine&lt;/ulink&gt; was longer acting with a more consistent release of NO than molsidomine and had shown efficacy in angina in a US phase IIa study [&lt;ulink linkID="167679" linkType="reference"&gt;167679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from a double blind randomized trial in 48 patients with documented coronary artery disease and exercise induced ST-segment depression was presented at the XVIIth Congress of the European Society of Cardiology in Amsterdam, August 1995. Pulmonary hemodynamics and ischemic parameters were examined at rest and during exercise one hour after placebo or 10, 20, or 40 mg &lt;ulink linkID="4134" linkType="Drug"&gt;pirsidomine&lt;/ulink&gt; orally. The results showed a dose dependant reduction in diastolic pulmonary artery pressure with &lt;ulink linkID="4134" linkType="Drug"&gt;pirsidomine&lt;/ulink&gt; during exercise compared to placebo. Further, ST-segment pressure was decreased and exercise duration was increased compared to placebo. Blood pressure, cardiac output and heart rate showed no significant variations [&lt;ulink linkID="186084" linkType="reference"&gt;186084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="4134" linkType="Drug"&gt;Pirsidomine&lt;/ulink&gt; belonged to the sydnonimine group of compounds and was a prodrug that is metabolized into a NO-releasing metabolite [&lt;ulink linkID="186261" linkType="reference"&gt;186261&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="178">Hypertension</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="178">Hypertension</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="23">Angina</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="23">Angina</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="178">Hypertension</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="23">Angina</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00897"><Name>Guanylate cyclase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Chemical Structure Added/Updated</Reason><Description>Chemical structure added or updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@@H]1CCC[C@@H](N1[n+]2cc(on2)[N-]C(=O)c3ccc(cc3)OC)C</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>